erlotinib hydrochloride has been researched along with gadolinium dtpa in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (gadolinium dtpa) | Trials (gadolinium dtpa) | Recent Studies (post-2010) (gadolinium dtpa) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 12,654 | 664 | 4,051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barboriak, DP; Brizel, DM; Carroll, MD; Cleland, E; Craciunescu, OI; MacFall, JR; Muradyan, N; Yoo, DS | 1 |
1 trial(s) available for erlotinib hydrochloride and gadolinium dtpa
| Article | Year |
|---|---|
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Area Under Curve; Bevacizumab; Chemoradiotherapy; Cisplatin; Contrast Media; Erlotinib Hydrochloride; Gadolinium DTPA; Head and Neck Neoplasms; Humans; Image Enhancement; Lymphatic Metastasis; Magnetic Resonance Imaging; Microcirculation; Molecular Targeted Therapy; North Carolina; Quinazolines | 2012 |